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ABSTRACT
Background: Patients with blood clotting disorders have severely depleted levels of
blood clotting factor (BCF) proteins in their blood, which results in a significantly higher
risk of bleeding events than a typically healthy patient. Serotonin based antidepressant
medications, such as selective serotonin reuptake inhibitors (SSRI) or serotonin
norepinephrine reuptake inhibitors (SNRI) alter the levels of serotonin in the blood as a
mechanism to treat depression.
Serotonin is used for many different chemical processes within the body including blood
aggregation. We sought to quantify the potential risk associated with the use of these
types of antidepressant medications to patients with blood clotting disorders.

Objective: To determine if patients with BCF disorders who are prescribed SSRI or
SNRI medications are at an increased risk of having a major bleeding event.

Methods: A retrospective cohort study was conducted using data from the Optum
Clinformatics Data Mart. An initial cohort of 16,124 patients with blood clotting
disorders was formed; patients were excluded based upon enrollment eligibility, drug
prescription date outside the study timeframe, and age under 12 years. A final study
sample of 7,998 patients was formed. A follow up period of six months was selected to
analyze major bleeding events; these events were identified using ICD-9 codes for
hemorrhages. Patients were classified as to whether a bleeding event occurred during the
period. The use of antidepressant medications was determined by prescription drug

dispensings three months prior to the follow up period. Both univariate and multivariate
logistic regression models were built to enhance a final multivariate predictive model.
Results: The use of SSRI and SNRI antidepressant medications was not associated with
an increased risk of bleeding events (p=0.93). Risk factors for having a major bleeding
event included older age (P=<0.0001), male gender (P=<0.0001), diabetes (P=0.0001),
nonsteroidal anti-inflammatory drug (NSAID) use (p=0.0040), anticoagulant use
(P=<0.0001), and Hemophilia A (p=0.0001). Patients who were between 46-65 years old
were 1.85 times more likely to have a major bleeding event than those between the ages
of 26-45 (95% CI: 1.31-2.61). This risk increases to 3.47 times for those between the
ages of 66-90 (95% CI: 2.36-5.11). Males were 1.84 times more likely to have a major
bleeding event in comparison to females (95% CI: 1.42-2.38). Patients who had diabetes
are at 1.84 times the risk of a major bleeding event than those with diabetes (95% CI:
1.35-2.52). Patients with Hemophilia A had approximately twice the risk of experiencing
a bleeding event as compared with patients having other blood clotting disorders (OR
2.13; 95% CI: 1.54-2.93).
Conclusion: SSRI and SNRI antidepressant medications were not associated with an
increased risk of bleeding events in this study. Factors associated with major bleeding
events included male gender, older age, the use of NSAIDs or anticoagulants, and a
diagnosis of Hemophilia A.
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CHAPTER 1
INTRODUCTION
Blood Clotting Factor disorders (BCF) are defined as inherited disorders that affect the
body’s ability to clot blood, thus increasing the frequency and duration of bleeding
events. There are 12 different BCF proteins within the human body responsible for blood
coagulation. (1) The most common types of BCF disorders are Hemophilia A,
Hemophilia B, and Von Willebrand disorder. Hemophilia is an extremely rare disease;
there are an estimated 20,000 cases in the U.S. (2) Hemophilia is a life-long disease that
is typically diagnosed at an extremely young age either by blood test or by the occurrence
of a bleeding event. Von Willebrand disease (VWD) is the most common BCF disorder
that affects approximately 1% of the population. (3) VWD is a genetically inherited
deficiency in the clotting protein which binds BCF VIII to the vessel walls. VWD occurs
equally in both men and women; hemophilia occurs almost solely in the male population.
(2, 3) This is due to hemophilia being an X-linked chromosome disease. The male
chromosome consists of both an X and a Y chromosome while the female chromosome
has two X. For a male to inherit hemophilia the trait only has to be present in the mother,
while a female would need both the mother and father to have a hemophilia mutation. In
most cases females who inherit the hemophilia trait will be a carrier, but they will not
exhibit symptoms. (4)
Patients with hemophilia can be categorized based upon their severity of disease.
Approximately 60% of patients with hemophilia are considered to be severe cases having
less than 1% of normal BCF activity, approximately 15% are moderate cases ranging
from 1-5%, and approximately 25% are mild cases ranging from 5-40%. (4) Patients with
1

severe hemophilia can experience a bleed (minor or major event) once or twice a week,
while moderate cases experience a bleed approximately once a month, and mild cases
bleed only after surgery or trauma.(4) If left untreated hemophilia can cause serious
damage to joints, muscle tissue, and organ tissue as a result of continuous bleeding and
swelling.
Antidepressant medications are prescribed for numerous reasons including but not limited
to depression, attention-deficit hyperactivity disorder (ADHD), anxiety disorder, and
bipolar disorder.(5) It is estimated that approximately one in ten adults in the U.S. are
prescribed an antidepressant medication. (6) Due to the burden of disease, the prevalence
of depression among patients with hemophilia is approximately 37%. (7) Selective
Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors
(SNRI) are the most commonly prescribed classes of antidepressants prescribed in the
U.S.; in a study using data from the National Ambulatory Medical Care Survey
(NAMCS) it was found that 65% of all antidepressant drugs prescribed in 2000 were
SSRI, while newer SNRI drugs accounted for 17% of the antidepressant utilization. (8)
Serotonin based antidepressants can affect the body’s ability to clot blood, this may have
potential negative repercussions for patients with depleted BCF activity.
SSRI and SNRI drugs impair platelet aggregation by preventing serotonin reabsorption.
(9, 10) Serotonin is an important neurotransmitter indirectly involved in platelet
aggregation. Coated-platelets are rich in collagen, thrombin, and prothrombinase, a serine
based protein that activates the proteins responsible for procoagulant activity. (11)
Coated-platelets clot a bleed by adhering to the wall of the blood vessel (von Willebrand
factor protein produced by the vessel walls), other platelets then crash into the adhered
2

platelets and begin to clump together due to the collagen and thrombin. This webbing
created by the platelets coated with collagen and thrombin, traps red blood cells as well
as other proteins in the blood to create a clot. Reducing the level of serotonin available
will diminish the levels of coated-platelets in the blood.
We hypothesize that patients who are prescribed SSRI or SNRI medications will be more
likely to experience a major bleeding event than those not using an SSRI or SNRI
antidepressant medication. Furthermore, we hypothesize that patients with BCF disorders
would be prescribed different classes of antidepressant medications as a result of this
increased risk. The objective of this study is to determine if patients with BCF who are
prescribed SSRI or SNRI antidepressants are at a higher risk of a major bleeding event
occurring. A secondary objective of our study is to describe the prescribing frequency of
antidepressant medication classes for patients with BCF disorders.
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CHAPTER 2
REVIEW OF THE LITERATURE
Although a literature review of studies comparing bleeding rates for patients with BCF
disorders and the potential impact of antidepressant medication yielded no direct results,
there was still enough relevant literature available to help provide a basis for this study.

Von Willebrand’s Disease is the most common genetic BCF disorder, found in 0.1-1% of
the population. Within this patient population it is estimated that 10% of patients display
symptoms of the disease. (12) Von Willebrand factor (vWF) is an adhesive glycoprotein
responsible for gluing platelets to the vessel wall to form a clot. James et al. (13)
identifies some of the major areas of bleeding associated with VWD: mucocutaneous
(mucosa/skin transition) and epistaxis (nasal) bleeding, as well as easy and frequent
tissue bruising. (13-15) Female patients frequently experience abnormally heavy bleeding
during menstruation (menorrhagia). (16) Fressinaud et al. (17) also notes that
gastrointestinal (GI) bleeding is reported in approximately 10% of VWD patients.

Hemophilia is a genetically transmitted disease on the X-chromosome. Both males and
females can inherit the disease, but typically only males exhibit symptoms. Females who
inherit the mutation for hemophilia are considered carriers and are not symptomatic. Plug
et al (18) conducted an analysis of bleeding in carriers of hemophilia compared to those
who are non-carriers. The researchers conducted this analysis using self-reported
information collected from a survey of 546 women within the Netherlands; of these
women, 274 were carriers of either hemophilia A or B. The researchers found that there
was a significant increase in bleeding events for patients who were carriers of hemophilia
4

when compared to non-carriers. They also reported a statistically significant increase in
the duration of bleeding for carriers after a tooth extraction, tonsillectomy, or operation.
Carriers were twice as likely (Relative Risk (RR), 2.3: 95 % Confidence Interval (CI), 1.5
to 3.4) to have a bleed lasting longer than three hours after one of these procedures when
compared to non-carriers. Hemophilia has an estimated incidence of 1 in 5,000 male
births. (2) Soucie et al. (2) conducted a study for the Center for Disease Control and
Prevention (CDC) in 1994, estimated that there were approximately 17,000 cases of
hemophilia (A and B) in the U.S. Using birth and death rates since that time the CDC
estimates that number has risen to approximately 20,000. (2) Males who inherit the
hemophilia trait will be symptomatic due to only inheriting the X chromosome from his
carrier mother and the Y from his father. Males who have hemophilia typically have
frequent minor bleeds. Major bleeding events are usually the result of surgery or trauma.
For male patients the majority of bleeding events occur internally and can result in
serious damage caused to joints, muscle tissue, and organ tissue due to continuous
bleeding and swelling. (2, 19)

A study conducted by Dawson et al (20) using commercial claims data from 2008-2013
was used to obtain a baseline measure for the utilization of each antidepressant drug class
among privately insured patients, irrespective of comorbidity. The study population
consisted solely of privately insured women age 15-44. The population ranged from 4.6
million to 6.8 million (per year) during the 5 year duration. They found that 15.4% of
women had a prescription for an antidepressant filled at least once a year. Antidepressant
drug claims were categorized by class: SSRI, SNRI, Tricyclic antidepressants (TCA),
Monoamine oxidase inhibitors (MAOI) and other. It was found that 10.7% of the study
5

population were prescribed a SSRI, 2.8% were prescribed an SNRI, 1.4% were
prescribed a TCA, 0% were prescribed a MAOI, and 3.9% were prescribed other types.
They also found that 11.7% of the population filled a prescription for only one class of
antidepressant, while 3.7% filled prescriptions for multiple classes of antidepressants.

A study by Turner et al. (9, 21, 22) details how SSRI drugs impact the likelihood of a
bleeding event. The authors explain how SSRIs impact platelet aggregation by preventing
serotonin from being reabsorbed at a normal rate. The authors concluded that the effect
on platelets by SSRI drugs may have a clinical importance when considering a patient’s
risk of bleeding.

Prodan et al. (11) detailed the clinical background of SSRIs and their impact on coatedplatelets. The authors explain that coated-platelets are rich in prothrombinase, a serine
based protein that activates proteins responsible for procoagulant activity. This study
found that patients prescribed SSRIs had a statistically significantly lower level of
coated-platelets in the blood, with an analysis of variance test which yielded a p-value of
0.046. The study also identified smoking and aspirin use as having a significant impact
on coated-platelet levels.

It is estimated that approximately one in ten adults in the United States (US) is prescribed
an antidepressant medication, for a range of indications. (6) It is important to note, due to
the burden of disease, the prevalence of depression among hemophilia patients is
estimated at 37%. Iannone et al. (7) identified three covariates that could have a
significant effect on the rate of depression for patients with hemophilia: unemployment
6

(P=0.01), lack of social support (p=0.04), and occurrences of bleeds per year (P=0.06).
This study determined that the increase in number of bleeding events per year was
slightly above the threshold for statistical significance; the study reported a 22% increase
in the odds of depression for every five bleeding episodes (per year). Barlow et al (23)
also reported that many hemophilia patients struggle with the physical burden of
hemophilia, with symptoms including joint bleeds and co-morbidities due to blood
transfusions. The authors discussed how these comorbidities diminish the patient’s
quality of life by affecting their education, work, and social activities.

This study will provide patients and physicians more knowledge about the effects of
SSRI and SNRI antidepressants use for patients with BCF disorders. The aim of this
study was to determine if patients who are prescribed a SSRI or SNRI medication are
more likely to experience a major bleeding event then those not using an antidepressant
medication. The study also determined prescribing frequencies for particular
antidepressant medications used in patients with BCF disorders.
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CHAPTER 3
METHODOLOGY
Study Population and Design
This study was conducted as a retrospective cohort study of privately insured U.S.
citizens who were continuously enrolled throughout 2012. The study population was
selected from the Optum Clinformatics Data Mart. Patients were deemed eligible if they
had continuous enrollment during the entire year of 2012. The population included
patients with Hemophilia A and B, Von Willebrand’s Disease, and other non-specified
blood clotting disorders. BCF disorders are typically diagnosed at an extremely young
age and persists throughout a patient’s lifetime. We formed our cohort to include all
patients having any of the International Classification of Diseases (ICD-9) diagnosis
codes designating a BCF disorder (286.0 - 286.5) available from 2010 to 2012. Most
antidepressant medications are not FDA approved for children under the age of 12. (6)
Based upon this information the inclusion criterion for age ranged from 12-100 years old.
A sample of 621 patients would be required for a cohort study based upon the following
characteristics: alpha=0.05, power=0.8, incidence=0.3, and a relative risk= 1.25. (24) By
expanding our study from hemophilia A to all BCF disorders we were able surpass the
required sample size and yield a study population of 7,998.

Dependent Variable:
Major bleeding events (hemorrhages) was the dependent variable used for this study.
Major bleeding events were identified using a series of ICD-9 codes for hemorrhages
validated in a study by Arnason et al (appendix 4). (25) A patient who had one or more
documented bleeding event, requiring an inpatient or outpatient visit during a 6 month
8

follow-up period (July 1, 2012 – December 31, 2016) were assigned a designation of 1,
whereas if no events occurred a designation of 0 was specified. The data source used in
our study captured only bleeding events that were serious enough to require medical
attention.

Independent Variables
SSRI or SNRI antidepressant use was the independent variable of interest. Patients were
classified as exposed to these medications if they received at least 1 drug claim for either
an SSRI or SNRI antidepressant during the 3 month period (April 1, 2016 – June 30,
2016) preceding the 6 month follow-up period for identifying bleeding events. Patients
without an SSRI or SNRI antidepressant drug claim during this 3 month period were
categorized as unexposed to these medications. Patients who initiated antidepressant drug
therapy after this 3 month period were excluded from the analysis. As antidepressant
polytherapy is common, we excluded users of non-SSRI/SNRI medications from our
multivariate analyses. To describe antidepressant medication utilization overall, we
determined the frequency of use of other antidepressant types including tricyclics,
MAOIs, serotonin modulators, and miscellaneous antidepressant drugs (Appendix 3). We
also created an independent variable describing the type of BCF disorder documented.
BCF types were categorized into four groups: Hemophilia A, Hemophilia B or C, VWD,
and other clotting factor/ intrinsic anticoagulants. Approximately 6% of the sample
population had ICD-9 codes for multiple blood clotting disorders; these patients were
included in the other clotting factor/ intrinsic anticoagulants group.

9

Independent Variables:
This study also investigated age, gender, geographic region, HIV, HEPC, and diabetes as
other variables that may impact the risk of a major bleeding event occurring. Values for
age, gender, and geographic region were determined during the three month baseline
period. HIV, HEPC, and diabetes status were determined using the available eligibility
period preceding the follow-up period. Age was tested as a continuous variable and as a
categorical variable for the predictive model; the categorical version of age was used to
display the distribution for descriptive statistics. The variable “U.S. state” was used to
form geographic regions, i.e. Northeast, Midwest, Southeast, Southwest, and West. (26)
There are numerous indications for which antidepressant drugs can be used.

Statistical analysis:
The analysis was conducted using the occurrence of at least one major bleeding episode
as the dependent variable. Descriptive statistics were applied to present the frequency and
percent of all variables, stratified by exposure and outcome status. Exposure to an SSRI
or SNRI antidepressant was the primary independent variable of analysis in this study. A
final logistic regression model was constructed using all variables deemed statistically
significant. We excluded patients from the multivariate model who were identified as
users of only other classes of antidepressant drugs (i.e. TCA, MAOI, serotonin
modulator, or miscellaneous antidepressant). We first created univariate logistic
regression models for each independent variable, testing each for a statistically significant
relationship with the study outcome of bleeding events. Univariate models with a P-value
< 0.20 were considered eligible for inclusion in the initial multivariate model. This
saturated logistic regression model included the variables age (continuous), gender,
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region, HIV, HEPC, diabetes, NSAID or anticoagulants, SSRI/ SNRI use, and BCF
disorder type (hemophilia A, Hemophilia B/C, VWD, and other/ multiple BCF
disorders). Variables within the model having a P-value<0.05 were considered
statistically significant for this preliminary model.

To construct a final model we used backwards selection to eliminate variables which
were included in model selection due to their statistically significant univariate p-values
(<0.20). Several models were tested against the saturated model for their goodness-of-fit;
with the intent to simplify a final model, creating the best predictive model possible. The
likelihood ratio test (LRT) statistic was used to evaluate the different models created.
Using the LRT statistic we concluded which variables should be included in the final
model, using the following equation:

-2(LRT initial model – LRT Complex model)= X -> Zscore -> Chi Sq P-value

Based upon the Chi-Sq distribution and p-value (corresponding to degrees of freedom),
we decided whether a variable should be included or excluded in the final model. The
Akaike information criterion (AIC) and Hosmer-Lemeshow test were also applied. A
smaller AIC value indicated a stronger model fit, while the Hosmer-Lemeshow uses the
Pearson Chi-Sq statistic to assess model fit. A correlation procedure was performed for
the 17 variables included in the saturated model. The objective of this correlation analysis
was to analyze the variables for collinearity effects. A correlation coefficient of 0 would
represent no correlation between the variables, thus they do not vary together. Variance
inflation factor (VIF) and tolerance values (TOL) were also analyzed to identify
11

multicollinearity among variables. VIF values greater than 10 would identify variables
with possible collinearity, while a minimum value for TOL of 0.20 would identify
variables with multicollinearity effects.(27) Statistically significant variables were tested
by creating new variable interaction terms, and testing models both with and without the
new variable. These models were tested against each-other using the -2logL equation:

-2(LRT initial model – LRT Complex model)= X -> Zscore -> Chi Sq P-value

If the Chi-Sq value was statistically significant a variable interaction would be identified.

A relative risk (RR) was calculated to evaluate the effect of the variables included in the
multivariate logistic regression model with risk of bleeding event, including a 95%
confidence interval of the point estimate. The RR reflects the increase in risk of bleeding
associated with a particular variable, and was calculated as the probability of an event
occurring in the exposed group (event=1) divided by the probability of an event occurring
in the unexposed group.
To analyze the prescribing frequency of all types of antidepressants, dispersions of the six
antidepressant classifications available were identified. Based upon the antidepressant
classes of interest and univariate analyses we further segmented three of the
antidepressant classes down to the drug level, SSRI (6 drugs), SNRI (3 drugs), and
serotonin modulators (3 drugs). (Appendix 2)
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CHAPTER 4
Results
Study population characteristics
There were 16,124 patients identified as having a blood clotting factor disorder during the
timeframe. Patients who did not have continuous enrollment through 2012 were excluded
(N=6855). We then excluded patients under the age of 12 (N=304), and next excluded
patients having a new a prescription for antidepressant medication occurring after the 3
month baseline exposure period (N=667). After all exclusions were applied the study
cohort was reduced to 7,998 patients. We identified 1,531 (19.1%) patients as being
prescribed an antidepressant medication during the 3 month baseline period. Of these
1,531 patients, we identified 876 as having an SSRI dispensing, and 377 who had an
SNRI dispensing. Using the ICD9 codes for hemorrhage listed in appendix 4, we
identified major bleeding events that occurred between 6/1/12 to 12/31/12. A total of 238
patients had at least one major bleeding event, among the 7,998 patients in the study
population (3.476%). Of these 238 patients who had a major bleeding event, 42 (3.4%)
were prescribed either an SSRI or SNRI antidepressant medication, while 196 (2.9%)
were not.
The study population’s predominant characteristics were 65.15% female, 40.67% of
patients were between 46-65 years old, 30% lived in the southeast, 0.79% of patients had
a diagnosis for HIV, 1.68% of patients had a diagnosis of HEPC, 13.43% of patients had
a diagnosis of diabetes, 20.63% were prescribed a NSAID, 12.59% were prescribed an
anticoagulant, 16.90% were prescribed an SSRI or SNRI, while 22.73% were prescribed
an antidepressant of any kind. The prevalence of major bleeding events within the study
population was 2.98%.
13

The bivariate analyses identified several variables that were associated with major
bleeding events: older age (p=0.0001), male gender (p=0.0001), diabetes (p=0.0001),
NSAID use (p=0.0004), anticoagulant use (p=0.0004), Hemophilia A (p=0.0004), and
VWD (p=0.0006).
Antidepressant drug utilization in this patient population was similar to that of the general
population. We found that 876 (57.2%) patients were prescribed an SSRI, 377 (24.6%)
patients were prescribed an SNRI, 150 (9.8%) patients were prescribed a TCA, less than
10 were prescribed an MAOI antidepressant, 171 (11.2%) received a serotonin
modulator, and 254 (16.6%) patients were prescribed an antidepressant classified as
miscellaneous. During the 3 month baseline period 1,265 patients received only one class
of antidepressant, 236 patients received 2 different classes of antidepressants, and 31
patients received 3 classes of antidepressant drugs.
The use of SSRI or SNRI antidepressants was more frequent among older patients,
females, and patients with diabetes (p < 0.0001 for all comparisons). Users of NSAIDs
and oral anticoagulants were also more likely to be prescribed SSRI or SNRI
antidepressants as compared with patients not receiving NSAIDs or oral anticoagulants (p
< 0.0001). Further detail is presented in Table 1c.

Univariate Logistic Regression Models
In univariate logistic regression analyses we identified variables having a statistically
significant association with the occurrence of a major bleeding event (Table 3). In the
univariate analysis, there was no significant increase in the occurrence of a bleeding
event among patients prescribed an SSRI or SNRI medication (P=0.68, RR=1.09, 95%
CI= 0.74 – 1.60). Univariate analyses were also conducted for age, gender, region, HIV,
14

HEPC, diabetes, and drugs known to affect bleeding. Age was tested as both a continuous
variable and a categorical variable, and both versions had a statistically significant effect
on the risk of bleeding (p=<0.0001). When analyzing age in categories there was a
noticeable increase in risk with advancing age. Using 26 to 45 years old as the reference
group, there was no difference in risk when compared to the age group 12 to 25 years old.
When comparing patients between the ages of 46-65 years to patients age 26-45 years of
age, the RR was 1.75 (CI: 1.23-2.51). For patients between 66 and 91 years of age
(reference 26-45 years), the risk of major bleeding was more than 3 times higher (RR
3.40; 95% CI: 2.27-5.08). A univariate model for patient gender was also tested using
female gender as the reference category. This model had a p=value of <0.0001 and a RR
of 1.83 (95% CI: 1.40-2.40). Based upon this information we can conclude that male
patients were at a significantly higher risk of having a major bleeding event as compared
with female patients. U.S. regions were also evaluated, but no statistically significant
effect was found between different geographic areas. Comorbidities of interest at the
beginning of this study were identified as HIV, HEPC, and diabetes. Due to contaminated
blood in the 1970’s and 1980’s many patients who required numerous blood transfusions
over time contracted HIV and HEPC. (28, 29) This study found no significant increase in
the risk of major bleeding events for patients with either disease. The RR for HIV was
1.80 (95% CI: 0.56-5.80) with a p-value=0.3245, and the relative risk for HEPC was 2.05
(95% CI: 0.94-4.45; p=0.0695). (Table 3) A univariate analysis assessing the influence
of diabetes revealed that patients with this disease were at an increased risk of a major
bleeding event occurring (RR 1.78; 95% CI: 1.27-2.49; p=0.0007). Lastly, a univariate
analysis was conducted analyzing drug classes that are known to increase the risk of
bleeding. Users of NSAIDs were 54% more likely to experience a bleeding event (RR
15

1.54; 95% CI: 1.14-2.08), while users of anticoagulants were twice as likely to
experience a bleeding event (RR 2.00; 95% CI: 1.43-2.78).

Univariate analyses were also conducted to assess bleeding risk according to type of BCF
disorder. We found that patients with Hemophilia A had a RR of 2.03 (95% CI: 1.522.72, p=0.0001); patients with Hemophilia B/C had a non-significant RR of 0.93 (95%
CI: 0.59-1.47, p= 0.7661), patients with VWD had a non-significant RR of 0.75 (95% CI:
CI: 0.54-1.03, p=0.0737), and those with other/multiple clotting factors had a RR of 1.12
(95% CI: 0.86-1.03, p= 0.4088). Based upon these findings we conclude that older age,
male gender, diabetes, NSAID use, anticoagulant use, and the presence of HEP-C,
Hemophilia A, and VWD met the selection criteria for advancing to the multivariate
model analysis.

Multivariate Logistic Regression Modeling
Two multivariate logistic regression models were constructed, a saturated model and a
reduced model which includes statistically significant variables or strata. The saturated
model (Table 4) included the variables age, gender, region, HIV, HEPC, diabetes, SSRI
or SNRI use, NSAID use, anticoagulant use, Hemophilia A, Hemophilia B/C, VWD, and
other/ multiple BCF disorders. Several variables were statistically significant in this
model: age, gender, NSAID use, anticoagulant use, and Hemophilia A (p <0.05 for all).
Within this model VWD was just above significance (p – 0.074). Next, a reduced model
was constructed using the variables determined to be statistically significant from the
univariate analyses. This reduced model included nine variables: age, gender, diabetes,
Hemophilia A, VWD, NSAID use, HEP-C, SSRI or SNRI use, and anticoagulant use.
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Based upon this model a final model was constructed eliminating non-significant
variables using backwards elimination. The final model included age, gender, NSAID
use, anticoagulant use, hemophilia A, VWD, and SSRI or SNRI use, as risk factors for
the occurrence of a major bleeding event. Based upon this final model we can conclude
that the risk of a major bleeding event was higher for males, the older population, those
patients prescribed NSAID or anticoagulant medications, and patients who had
Hemophilia A or VWD.

Discussion

BCF disorders are complex diseases to live with; patients must deal with sporadic
bleeding under normal conditions. Serotonin-based antidepressant medications lower
levels of serotonin in the blood, a necessary component in blood coagulation. Any
association between serotonin-based antidepressants and bleeding events would be a
relevant concern for BCF disorder patients and their physicians.

The results of our analyses revealed that age, gender, NSAID use, anticoagulant use, and
Hemophilia A were risk factors in major bleeding. This information coincides with the
results of other research available. Studies have revealed that as patients get older they
are at a significantly higher risk of bleeding events. (30-32) The risk of major bleeding
events due to NSAID use likely varies by patient as well as the duration of on NSAID
therapy. A 16 week study found that there was no increased risk of bleeding events for a
hemophilic taking 1600 mg of ibuprofen daily. (30) A study assessing upper
gastrointestinal bleeding in hemophiliacs found that patients taking an NSAID (naproxen,
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ibuprofen, or diclofenac) for less than one month were at a statistically significant
increased risk of GI bleeding. They also reported that patients with prolonged NSAID use
(>1 month) were not at an increased risk of bleeding. The researchers further reported
that Cox-2-inhibitors (Rofecoxib and Celecoxib) are a safer alternative to NSAIDs for
hemophiliac patients. (31) There is little information known about the risk of bleeding in
BCF patients taking anticoagulants. Our study results correspond to the known risks of
anticoagulants in the general population. (33) Additionally, we tested two-way variable
interactions but did not identify any interaction effects between the variables included in
our study.

We did not identify an association between SSRI or SNRI use and major bleeding events
in our study; although other studies have shown that there is a moderate increase in
particular types of bleeding among patients using these drugs. Castro et al. (34) found
that patients who used antidepressant medications that have a high affinity for serotonin
transporters had an increase in the likelihood of gastrointestinal bleeding. A metaanalysis conducted by Hackam et al. (35) found an association between SSRI use and
intracranial hemorrhages (adjusted RR: 1.51; 95% CI: 1.26-1.81). Their analysis also
found an association between SSRI use and intracerebral hemorrhages (adjusted RR:
1.68; 95% CI: 1.46-1.91), and an increase in risk in patients who were taking both SSRIs
and anticoagulants (RR 1.61; 95% CI: 1.04-2.51).

Strengths and Limitations:
Due in part to the rarity of hemophilia and other bleeding disorders, there exists little
information published about antidepressant use in the hemophilia population. This study
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provides only a preliminary investigation of the risk associated with antidepressant use
among patients with BCF disorders using a retrospective cohort design. Further study
examining particular SSRI and SNRI medication products and hemorrhage types may
reveal increases in bleeding risk that were not evident in our aggregate analyses. Our
analysis highlighted age, gender, and NSAID/ anticoagulant use as key risk factors for
the occurrence of bleeding events. This study also provides descriptive statistics detailing
the antidepressant medication classes used among this sample of patients having a BCF
disorder, finding that SSRI and SNRI medications were commonly prescribed.

There were limitations of this study to be noted. The primary limitation of this study
relates to data source, which was collected by a national health insurance company, and is
based upon individual patient healthcare claims. We were only able to capture episodes
of bleeding that that were serious enough to require medical care. Other limitations of
claims data include a lack of detail about the event (intensity and outcomes), lack of
patient history and demographics, and pharmacy claims do not indicate if the patient
actually ingested the drug. Claims data also lack information about the patient’s severity
of disease and bleeding treatment course (prophylactic or acute treatment).

The sample sizes for users of the antidepressant medications fluvoxamine, olanzapine/
fluoxetine, venlafaxine, and nefazodone were all less than or equal to 10 total patients. In
these instances it was possible that no bleeding events occurred because the sample size
was so small. Another limitation to this study is the inability to identify major bleeding
events as being related to antidepressant use, and not as a result of some other factor. We
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may have also failed to identify patients having diseases such as diabetes, HIV and HEPC
if no recent claim associated with these conditions was submitted.

Bleeding events were recorded as either the patient had at least one bleeding event
requiring medical attention, or they did not. We did not ascertain the frequency of
bleeding events per patient. We were also unable to identify bleeding events due to
trauma or illness. Lastly, the generalizability of this study population may not extend to
all patients with BCF disorders beyond the commercially insured. These results should
not be generalized to programs such as Medicaid or Medicare.

Further research using data collected at hemophilia treatment centers or questionnaires
from patients may be able to capture less severe bleeding events. It would also be worth
investigating the association between antidepressant use and the duration of bleeding
events. Being able to expand the type and number of bleeding events that occur may add
further insight into a potential association between antidepressant use and bleeding events
in the BCF disorder population.
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CHAPTER 5
CONCLUSION
Serotonin based antidepressant medications are known to alter the serotonin levels within
the blood. Altering serotonin levels reduce the concentration of coated-platelets within
the blood responsible for blood clotting. There is little known information on the
association between antidepressant use and episodes of major bleeding in patients with
blood clotting factor disorders.

This study did not identify an association between the use SSRI or SNRI antidepressant
medications and an increase in the occurrence of major bleeding events. Other important
risk factors for major bleeding that were identified in our study included advancing
patient age, male gender, and the use of NSAIDs and oral anticoagulants.
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APPENDIX 1: TABLES
Table 1a: Demographic and Clinical Characteristics of Patients with Blood Clotting
Factor Disorders and Association with the Occurrence of a Bleeding Event (N=7,998)
At least 1
Chi-Sq
No Bleeding Event
Bleeding
P-Value
Event
Cohort
7760 (97%)
238 (3%)
Population
<0.0001
Age
12-25 Years old
1,116 (98.20%)
20 (1.80%)
26-45 Years old
2,563 (98.16%)
48 (1.84%)
46-65 Years old
3,144 (96.64%) 109 (3.35%)
66-91 Years old
937 (93.89%)
61 (6.11%)
Gender
<0.0001
Female
5090 (97.68%) 121 (2.32%)
Male
2670 (95.80%) 117 (4.20%)
Region
0.9390
1,288 (97.21%)
37 (2.79%)
Northeast
2,322 (96.79%)
77 (3.21%)
Southeast
61 (2.90%)
Midwest
2,039 (97.10%)
1,083 (97.22%)
31 (2.78%)
West
32 (3.02%)
Southwest
1,027 (96.98%)
0.4367
HIV
Yes
60
<5
0.1225
HEPC
Yes
127 (94.78%)
7 (5.22%)
0.0001
Diabetes
Yes
1,022 (95.16%)
52 (4.84%)
0.0004
NSAID Use
Yes
1,579 (95.70%)
71 (4.30%)
0.0004
Anticoagulant Use
Yes
959 (95.23%)
48 (4.77%)
SSRI
0.8440
Yes
849 (96.92%)
27 (3.08%)
SNRI
0.0726
Yes
360 (95.49%)
17 (4.51%)
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Table 1b: Occurrence of a Bleeding Event by Type of Blood Clotting Factor Disorder
(N=7,998)
Bleeding Event P-value
0.0004
966 (95.64%)
44 (4.36%)
0.7668
587 (97.02%)
18 (2.98%)
0.0006
1,786 (98.13%)
34 (1.87%)
0.4088
No Event
Hemophilia A
Yes
Hemophilia B/ C
Yes
VWD
Yes
Other Clotting Factors/
Intrinsic Anticoagulants
Yes

4,421 (96.89%)
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142 (3.11%)

Table 1c: Exposure to SSRI or SNRI Antidepressants by Patient Characteristic (N=7,998)
No Exposure to
SSRI or SNRI
Cohort Population
Age
12-25 Years old
26-45 Years old
46-65 Years old
66-91 Years old
Gender
Female
Male
Region
Northeast
Southeast
Midwest
West
Southwest
HIV
Yes
HEP-C
Yes
Diabetes
Yes
NSAID Use
Yes
Anticoagulant Use
Yes

Exposure to
SSRI or SNRI

P-Value
<0.0001

1,050 (92.40%)
2,239 (85.75%)
2,658 (81.71%)
813 (82.87%)

86 (7.60%)
372 (14.25%)
595 (18.29%)
168 (17.13%)
<0.0001

4,246 (81.48%)
2,527 (90.67%)

965 (18.52%)
260 (9.33%)
0.4986

1,161 (87.62%)
2,002 (83.41%)
1,755 (83.57%)
953 (85.55%)
902 (85.17%)

164 (12.38%)
398 (16.59%)
345 (16.43%)
161 (14.45%)
157 (14.83%)
0.0567

59

>5
0.9002

114 (85.07%)

20 (14.93%)
<0.0001

852 (79.33%)

222 (20.67%)
<0.0001

1,333 (80.79%)

317 (19.21%)
<0.0001

782 (77.66%)
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225(22.34%)

Table 2a: Frequency of Antidepressant Use by Drug Class (n=1,531)
Antidepressant Class

Number of Patients (%)

SSRI

876 (57.2%)

SNRI

377 (24.6%)

TCA

150 (9.8%)

MAOI

<5

Serotonin Modulator

171 (11.2%)

Miscellaneous

254 (16.6%)

* Patients can be represented in multiple classes due to combination therapy
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Table 2b: Frequency of a Bleeding Event by Antidepressant Medication Type (N=1,531)

Drug
SSRI
Citalopram
Yes
Escitalopram
Yes
fluoxetine
Yes
Fluvoxamine
Yes
Paroxetine
Yes
Sertraline
Yes
SNRI
Duloxetine
Yes
Desvenlafaxine
Yes
Venlafaxine
Yes
Modulators
Nefazodone
Yes
Trazodone
Yes
Vilazodone
Yes

Patients experiencing a
bleeding event n (%)

253 (16.5%)
166 (10.8%)
154 (10.0%)
6 (0.4%)
63 (4.1%)
261 (17.0%)

176 (11.5%)
48 (3.1%)
156 (10.2%)

<5
156 (10.2%)
15 (1.0%)
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Table 3: Univariate Logistic Regression Analyses: Risk of Bleeding Events in Patients
with Blood Factor Clotting Disorders; Risk According to Demographics, Clinical
Characteristics and Antidepressant Use
Univariate models
age (continuous)
Age (categorical)
12-25 years old
26-45 years old (ref)
46-65 years old
66-91 years old
Gender
Female (ref)
Male
Region
Northeast
Midwest
Southeast
Southwest
West

OR (95% CI)
1.02 (1.01-1.03)

P-Value
<0.0001
<0.0001

0.88 (0.50-1.53))
1.00
1.75 (1.23-2.51)
3.40 (2.27-5.08)
<0.0001
1.00
1.83 (1.40-2.40)
0.86
1.00
0.95 (0.62-1.46)
1.14 (0.76-1.71)
1.05 (0.64-1.73)
0.95 (0.58-1.56)
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Table 3 continued: Univariate Logistic Regression Analyses: Risk of Bleeding Events in
Patients with Blood Factor Clotting Disorders; Risk According to Demographics, Clinical
Characteristics and Antidepressant Use
Comorbidities
HIV
no (ref)
yes

OR (95% CI)

P-Value
0.3245

1.00
1.80 (0.56-5.80)

HEPC
no (ref)
yes

1.00
2.05 (0.94-4.45)

0.0695

Diabetes
no (ref)
yes

1.00
1.78 (1.27-2.49)

0.0007

NSAID Use
no (ref)
Yes

1.00
1.54 (1.14-2.08)

Anticoagulant Use
no (ref)
yes

1.00
2.00 (1.43-2.78)

Antidepressant Class
SSRI or SNRI
no (ref)
yes
Hemophilia A
Yes
Hemophilia B/ C
Yes

0.0051

<0.0001

OR (95% CI)

P-Value
0.6795

1.00
1.09 (0.74-1.60)
<0.0001
2.03 (1.52-2.72)
0.7661
0.93 (0.59-1.47)

VWD

0.0737
Yes

Other Clotting Factors/
Intrinsic Anticoagulants
Yes

0.75 (0.54-1.03)

0.4088
1.12 (0.86-1.45)
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Table 4: Risk of Bleeding Events According to Demographic, Clinical Characteristics,
and Antidepressant Medication Use: Saturated Logistic Regression Model
Variable
OR (95% CI)
1.02 (1.01-1.03)
Female
Male

1.00
1.51 (1.13-2.00)

Northeast
Midwest
Southeast
Southwest
West

1.00
0.93 (0.61-1.42)
1.03 (0.69-1.54)
0.99 (0.61-1.62)
0.90 (0.55-1.47)
1.19 (0.36-3.93)
1.32 (0.95-1.84)
1.63 (0.73-3.61)
1.56 (1.14-2.13)
1.98 (1.40-2.80)
1.00 (0.67-1.50)
2.37 (1.64-3.42)
1.15 (0.70-1.92)
1.49 (0.98-2.26)

P-Value
<0.0001
0.0052
Ref
0.0052
0.9178
Ref
0.5867
0.9146
0.9881
0.5981
0.9534
0.2599
0.6878
0.0065
<0.0001
0.9898
<0.0001
0.5770
0.0625

1.29 (0.90-1.85)

0.1610

Age
Gender

Region

HIV
Diabetes
Hepatitis C
NSAID Use
Anticoagulant Use
SSRI or SNRI
Hemophilia A
Hemophilia B/ C
VWD
Other Clotting Factors/
Intrinsic Anticoagulants
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Table 5: Risk of Bleeding Events According to Demographic, Clinical Characteristics,
and Antidepressant Medication Use: Fitted Multivariate Logistic Regression Model
Multivariate models
Age
Male gender
NSAID Use
Anticoagulant Use
Hemophilia A
VWD
SSRI or SNRI Use

OR (95% CI)
1.02 (1.02-1.03)
1.53 (1.15-2.02)
1.66 (1.18-2.35)
2.22 (1.55-3.17)
2.12 (1.54-2.93)
1.27 (0.88-1.84)
1.02 (0.68-1.1)
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P-Value
<0.0001
0.0031
0.0039
<0.0001
<0.0001
0.2010
0.9325

APPENDIX 2: Flow Charts
Figure 1: Study Sample Selection Flow Chart
Antidepressant Cohort

Medical Cohort
Initial Study Population:

Patients with a prescription drug claim for a
SSRI, SNRI, Tricyclic, monoamine, serotonin
modulator, and miscelaneous:

16,124 Patients

2,952 Patients

Continuously enrolled
from 1/1/12 to 12/31/12:
9269 Patients

Those whose first prescription
drug claim occurred 6/1/12 were
EXCLUDED:
667 Patients
Patients with antidepressant drug claims
submitted from 3/1/12 to 6/1/12, and had
existing medical records:
1,994 Patients

Age >12: 8,665 Patients

Antidepressant
Exposure:
1,531 Patients

Those of SSRIs:
876 Patients

Cohort: 7,998 Patients

Those on SNRIs:
377 Patients

SSRI: Selective Serotonin Reuptake Inhibitor
SNRI: Serotonin Norepinephrine Reuptake Inhibitor
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Figure 2: Frequency of Utilization of Antidepressant Medications

All Antidepressant
Exposures:
1,531 Patients

SSRI:
876 (57.2%)

SNRI:
377 (24.6%)

Citalopram:
253 (16.5%)
Patients

Duloxetine:
176 (11.5%)
Patients

Nefazodone:
< 5 patients

Escitalopram:
166 (10.8%)
Patients

Desvenlafaxine:
48 (3.1%)
Patients

Trazadone:
156 (10.2%)
Patients

Fluvoxamine:
6 (0.4%) Patients

Venlafaxine:
153 (10.1%)
Patients

Tricyclics:
150 (9.8%)

Modulators:
171 (11.2%)

Vilazodone:
15 (1.0%)
Patients

Fluoxetine:
152 (10.0%)
Patients
Paroxetine:
63 (4.1%)
Patients

Sertraline:
261 (17.0%)
Patients
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Note: some patients were prescribed
multiple antidepressant classes or
drugs during the index period.

Monoamines:
< 5 Patients

miscellaneous:
254 (16.6%)

APPENDIX 3: Diagnosis codes for blood clotting disorders, hemorrhages, and drug class
codes
Blood Clotting Factor Disorders
Congenital factor VIII disorder (hemophilia A)
Congenital factor IX disorder (Hemophilia B)
Congenital factor XI deficiency (Hemophilia C)
Congenital deficiency of other clotting factors
Von Willebrand's disease
Hemorrhagic disorder due to intrinsic circulating anticoagulants

ICD-9 Code
286.0
286.1
286.2
286.3
286.4
286.5

Antidepressant drug classifications
Selective Serotonin Reuptake Inhibitor
Serotonin Norepinephrine Reuptake Inhibitor
Tricyclics
Monoamine Oxidase Inhibitors
Antidepressants, Miscellaneous
Serotonin Modulators

Optum code
28160420
28160416
28160428
28160412
28160492
28160424

Other drugs
Anticoagulants, Miscellaneous
Heparins
Direct Factor Xa Inhibitors
Direct Thrombin inhibitors
Coumarin Derivatives
Cyclooxygenase=2 (COx-2) Inhibitors
Salicylates
Other NSAIDs Agents

Code
20120492
20120416
20120414
20120412
20120408
28080408
28080424
28080492

Comorbidities

ICD-9 Codes
HIV
V08
AIDS
042
HIV-2
07953
Human T-cell lymphotrophic virus, type 1 (HTLV-I)
07951
HIV counseling
v6544
Acute Hepatitis C with Hepatic Coma
07041
Chronic Hepatitis C With Hepatic Coma
07044
Chronic Hepatitis C without Hepatic Coma
07054
Unspecified Viral Hepatitis C without Hepatic Coma
07070
Unspecified Viral Hepatitis C with Hepatic Coma
07071
Diabetes Mellitus w/o mention of complications, Type II, controlled
25000
Diabetes Mellitus w/o mention of complications, Type I, controlled
25001
Diabetes Mellitus w/o mention of complications, Type II, uncontrolled
25002
Diabetes Mellitus w/o mention of complications, Type I, uncontrolled
25003
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APPENDIX 4: Identifying bleeding events using ICD-9 codes for Hemorrhages (25)
description
hemopericardium
subarachnoid hemorrhage
intracerebral hemorrhage
Nontraum extradural hem
Subdural hemorrhage
Intracranial hemorr NOS
int hemrrhoid w comp nec
ext hemrrhoid w comp nec
hemrrhoid NOS w comp nec
hemorrhage NOS
esophag varices w bleed
esoph varices in oth dis
mallory–weiss syndrome
esophageal disorder nec
ac stomach ulcer w hem
ac stomach ulcer w hem-obst
ac stomach ulc w hem/perf
ac stomach ulc w hem/perf-obst
chr stomach ulc w hem
chr stomach ulc w hem-obst
chr stomach ulc hem/perf
chr stomach ulc hem/perf-obst
ac duodenal ulcer w hem
ac duodenal ulcer w hem-obst
ac duodenal ulc w hem/perf
ac duodenal ulc w hem/perf-obst
chr duoden ulcer w hem
chr duoden ulcer w hem-obst
chr duoden ulc w hem/perf
chr duoden ulc w hem/perf-obst
ac peptic ulc w hemorr
ac peptic ulc w hemorr-obst
ac peptic ulc w hem/perf
ac peptic ulc w hem/perf-obst
chr peptic ulcer w hem
chr peptic ulcer w hem-obst
chr peptic lc w hem/perf
chr peptic lc w hem/perf-obst
ac marginal ulcer w hem
ac marginal ulcer w hem-obst
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Code
423
430
431
432
432.1
432.9
455.2
455.5
455.8
459
456
456.2
530.7
530.8
531
531.01
531.2
531.21
531.4
531.41
531.6
531.61
532
532.01
532.2
532.21
532.4
532.41
532.6
532.61
533
533.01
533.2
533.21
533.4
533.41
533.6
533.61
534
534.01

ac margin ulc w hem/perf
ac margin ulc w hem/perf-obst
chr marginal ulcer w hem
chr marginal ulcer w hem-obst
chr marg ulc w hem/perf
chr marg ulc w hem/perf-obst
acute gastritis with hemorrhage
Atrophic gastritis with hemorrhage
gastr mucosoal hypertroph with
hemorrhage
alcoholic gastritis with hemorrhage
gastritis nec with hemorrhage
gastritis/duodenitis NOS with hemorrhage
duodenitis with hemorrhage
gastroduodenal dis nec
diverticula sm intestine w hemorrhage
diverticulitis sm intestine w hemorrhage
diverticula of colon w hemorrhage
diverticulitis of colon w hemorrhage
hemoperitoneum
rectal and anal hemorrhage
angiodysplasia with hem nec
hematemesis
blood in stool
Gastrointest hemorr NOS
renalvascular disorder
hematuria
noninflam dis vagina nec
excessive menstruation
metrorrhagia
hemarthrosis (nonspecific)
hemarthrosis (shoulder)
hemarthrosis (upper arm)
hemarthrosis (forearm)
hemarthrosis (hand)
hemarthrosis (pelvis)
hemarthrosis (leg)
hemarthrosis (ankle)
hemarthrosis (joint, neck)
epistaxis
Hemorrhage from throat
hemoptysis
35

534.2
534.21
534.4
534.41
534.6
534.61
535.01
535.11
535.21
535.31
535.41
535.51
535.61
537.8
562.02
562.03
562.12
562.13
568.81
569.3
569.85
578
578.1
578.9
593.81
599.7
623.8
626.2
626.6
719.1
719.11
719.12
719.13
719.14
719.15
719.16
719.17
719.18
784.7
784.8
786.3

APPENDIX 5: IRB exempt approval
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